Ceftriaxone Injectables: An In vitro Evaluation of Antimicrobial Activity and Comparative Efficacy

Abstract

Aims: The objective of the current study was to compare the In Vitro efficacy of regionally produced brands of ceftriaxone with that of the global innovator brand. Therefore, a fact-based conclusion at the end of the study will serve to dispel any uncertainty regarding the efficacy of medications produced locally, whether they are inferior or equal in their comparative activity. Study Design:  This study was In Vitro Lab based study. Place and Duration of Study: The study was performed in Riphah International University, Department of Pharmacy from July 2021 to August 2021. Methodology: Five regional brands and one international parent brand (Rocephin) were chosen. The multinational product was regarded as the standard. Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aurogenosa were the four bacterial strains against which activities were tested. Antibiotics' zone of inhibition was measured using the agar well method, and their minimum inhibitory concentration was identified using the broth dilution method. Results: All tested brands showed effectiveness against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aurogenosa.Some of the brands at some point showed more In Vitro efficacy than the standard brand. Conclusion: Health care professionals can be confident in prescribing locally manufactured brands that have equivalent efficacy to their international counterparts based on the findings of the study. Healthcare professionals can suggest the generic brand in population where medicine cost is directly affecting the patients adherence to therapeutic regimen.